Company Encyclopedia
View More
name
KHB
002022.SZ
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium.
1.579 T
002022.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking77/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-21.25%E
    • Profit Margin-46.93%E
    • Gross Margin36.91%C
  • Growth ScoreE
    • Revenue YoY-14.61%E
    • Net Profit YoY-123.38%E
    • Total Assets YoY-12.97%E
    • Net Assets YoY-21.07%E
  • Cash ScoreD
    • Cash Flow Margin-213.08%D
    • OCF YoY-14.61%E
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio27.53%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    KHB: Net profit loss of 99.0801 million yuan in the third quarter, a decrease of 42.20%

    KHB announced that its revenue for the third quarter was 398 million yuan, a year-on-year decrease of 9.96%; the net profit loss was 99.0801 million yuan, a decrease of 42.20%. The revenue for the first three quarters was 1.191 billion yuan, a year-on-year decrease of 11.77%; the net profit loss was 233 million yuan, a decrease of 90.38%

    Zhitong·
    SZ
    002022
    +0.46%
    Zhitong·
    SZ
    002022
    +0.46%

    KHB's product has obtained a medical device registration certificate

    According to the Zhitong Finance APP, KHB announced that the company recently received a medical device registration certificate (in vitro diagnostic reagents) issued by the Shanghai Municipal Drug Administration. The product involved is the ferritin assay kit (latex immunoturbidimetric method). This kit is used by medical institutions for the quantitative determination of ferritin (FER) levels in human serum and plasma samples. Clinically, it is mainly used for the auxiliary diagnosis of iron metabolism-related diseases, such as hemochromatosis and iron deficiency anemia

    Zhitong·
    SZ
    002022
    +0.46%
    Zhitong·
    SZ
    002022
    +0.46%

    KHB convertible bond repurchase results announced, 70 bonds repurchased for a total amount of 7,016.87 yuan

    Shanghai KHB Biotechnology Co., Ltd. announced the repurchase results of the "KHB Convertible Bonds." The repurchase declaration period is from September 10, 2025, to September 16, 2025, with a repurchase price of 100.241 yuan per bond. The number of valid declarations is 70 bonds, with a total repurchase amount of 7,016.87 yuan. The funds will be credited on September 19, and allocated on September 22, with investors receiving the payment on September 23. This repurchase has no significant impact on the company's finances, and the unrepurchased "KHB Convertible Bonds" will continue to be traded on the Shenzhen Stock Exchange

    Zhitong·
    SZ
    002022
    +0.46%
    Zhitong·
    SZ
    002022
    +0.46%

    KHB and others established a medical technology company, including the sales business of bio-based materials

    According to the Qichacha APP, recently, Jiangsu Tianlong Medical Technology Co., Ltd. was established, with Liang Jiaming as the legal representative and a registered capital of 10 million yuan. The business scope includes: operation of Class III medical devices; sales of Class II and III radiation devices; software outsourcing services; development of basic artificial intelligence software; sales of bio-based materials, etc. Qichacha's equity penetration shows that the company is jointly held by KHB Holdings Company Xi'an Tianlong Technology Co., Ltd. and Hainan Yikang Medical Technology Co., Ltd

    Zhitong·
    SZ
    002022
    +0.46%
    Zhitong·
    SZ
    002022
    +0.46%

    KHB released its performance for the first half of the year, with a net loss attributable to the parent company of 133 million yuan

    According to the Zhitong Finance APP, KHB released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net loss attributable to shareholders of the listed company was 133 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, with a basic loss per share of 0.2595 yuan

    Zhitong·
    SZ
    002022
    +0.46%
    Zhitong·
    SZ
    002022
    +0.46%
    © 2025 Longbridge｜Disclaimer